MedTrace Logo

Phase Ia Malaria Vaccine Trial of Two Virosome-Formulated Peptides

NCT00400101 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2006-11-16

No results posted yet for this study

Summary

Influenza virosomes represent an innovative human-compatible antigen delivery system that has already proven its suitability for subunit vaccine design. The aim of the study was to proof the concept that virosomes can also be used to elicit high titers of antibodies against synthetic peptides derived from the circumsporozoite protein and from the apical-membrane-antigen 1 and that the formulations are safe in humans.

Conditions

  • Falciparum Malaria

Interventions

BIOLOGICAL

Virosome-formulated synthetic peptides (malaria vaccine)

Sponsors & Collaborators

  • Swiss Tropical & Public Health Institute

    lead OTHER

Principal Investigators

  • Blaise Genton, MD PhD · Swiss Tropical & Public Health Institute

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-11-30
Completion
2005-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00400101 on ClinicalTrials.gov